PRF Technologies (PRFX) Preferred Stock Liabilities (2019 - 2020)
PRF Technologies' (PRFX) quarterly Preferred Stock Liabilities came in at $6.6 million in Q2 2020, little changed on a QoQ basis from $6.6 million in Q4 2019.
PRF Technologies (PRFX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
PRF Technologies (PRFX) has 2 years of Preferred Stock Liabilities data on file, last reported at $6.6 million in Q2 2020.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $6.6 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $6.6 million (changed N/A YoY) and the FY2019 annual result came in at $6.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $6.6 million in Q2 2020, from $6.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $6.6 million in Q4 2019 to a low of $6.6 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | PRF Technologies | 647,973.00 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 6.62 Mn |
| Dec 31, 2019 | 6.62 Mn |